[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Pages 81553-81554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32877]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before January 
29, 2016 will be considered.

ADDRESSES: Technology Transfer Center, National Cancer Institute, 9609 
Medical

[[Page 81554]]

Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-
5515 or email [email protected].

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below, may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION:
    Title of invention: Thalidomide/lenolidomide/pomalidomide analogs 
that inhibit inflammation, angiogenesis.
    Description of Technology: Thalidomide and its close analogs 
(lenalidomide and pomalidomide) are widely used to treat a variety of 
diseases, such as multiple myeloma and other cancers, as well as the 
symptoms of several inflammatory disorders. However, thalidomide is 
known for its teratogenic adverse effects when first introduced 
clinically in the 1950s, and is associated with drowsiness and 
peripheral neuropathy. Hence, there is intense interest to synthesize, 
identify and develop safer analogs. Researchers at the National 
Institute on Aging's Drug Design and Development Section synthesized 
novel thalidomide analogs that demonstrate clinical potential without 
being teratogenic, as initially evaluated in in vivo zebrafish and 
chicken embryo model systems and in cell culture. These new compounds 
differentially provide potent anti-angiogenesis and/or anti-
inflammatory action. The agents have potential for development of new 
cancer therapies and treatment of a number of neurological and systemic 
disorders involving chronic inflammation and elevated TNF-alpha levels.
    Potential Commercial Applications:

--Cancer therapeutics
--Inflammatory disorders such as Crohn's disease, sarcoidosis, graft-
versus-host disease, and rheumatoid arthritis
--Neuroinflammatory disorders (acute: Traumatic brain injury and 
stroke; chronic: Parkinson's disease, Alzheimer's disease, multiple 
sclerosis)
    Value Proposition:
--Non-teratogenic
--Potent
    Development Stage:
In Vitro/Discovery
    Inventor(s):
    Nigel H. Greig (NIA), Weiming Luo (NIA), David Tweedie (NIA), 
William Douglas Figg, Sr. (NCI), Neil Vargesson (Univ. Aberdeen, 
Scotland), and Shaunna Beedie (NCI & Univ. Aberdeen, Scotland)
    Intellectual Property:
HHS Reference No. E-208-2015/0-US-01
    U.S. Provisional Patent Application No. 62/235, 105, filed 
September 30, 2015, entitled ``Thalidomide/lenolidomide/pomalidomide 
analogs that inhibit inflammation, angiogenesis''
    Licensing and Collaborative/Co-Development Research Opportunity: 
The National Institute on Aging seeks collaborators to license or co-
develop novel thalidomide analogs that demonstrate clinical potential 
without being teratogenic.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing and/or research collaboration and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].
    CFR Citation: 35 U.S.C. 209 and 37 CFR part 404

    Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2015-32877 Filed 12-29-15; 8:45 am]
BILLING CODE 4140-01-P